Zanolimumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD4 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
652153-01-0  |
| ChemSpider | none |
| UNII |
HG3L8885M0  |
| KEGG |
D06356 |
| Chemical and physical data | |
| Molar mass | 147 kg/mol |
| (what is this?) (verify) | |
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] The drug is currently undergoing Phase II trials.[5]
References
- ↑ Genmab initiates Phase II Study with HuMax-CD4 Archived May 16, 2008, at the Wayback Machine.
- ↑ "Archived copy". Archived from the original on April 11, 2010. Retrieved August 20, 2010.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ↑ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
- ↑ "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011.
This article is issued from Wikipedia - version of the 11/15/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.